Please login to the form below
Great expectations: the urgent need for common purpose in Alzheimer’s disease
By Andrew Harrison
Bringing the trial to the patient
By Gretchen Goller
Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew
Real-world studies
by Bill Row
-
Embracing technology and analyticsBy Diane Wass
-
Is it time for a more integrated and human-centric approach to Medical Affairs leadership?By Shairose Ebrahim
-
Rare disease trials Q&ABy Gretchen Goller and Valerie Legrand
-
Lonely planet: why there is dwindling value in pharma travelling aloneTo develop sustainable business models that establish value ‘beyond the pill’, collaboration is the best way forward
-
Accelerating diagnosis in rare diseaseBiopharmaceutical companies can drive effective partnerships and improve outcomes for all stakeholders and patients in the area of rare disease.
-
Accelerating innovationIpsen’s Alexandre Lebeaut on the French firm’s oncology plans, global focus and R&D approach
COVID-19 Updates and Daily News
Featured jobs
- FDA sets November date for expert panel review of Biogen’s aducanumab
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b
- Vaccine developers call on FDA to offer clarity on COVID-19 trials
- How will the events and exhibitions industry change post-Coronavirus?
- Novartis weathers the COVID-19 storm in Q3, lifts outlook
- Eli Lilly ends COVID-19 antibody trial in hospitalised setting, other studies continue
- Researchers say COVID-19 antibody levels have fallen rapidly in the UK
- Exploring the potential of eosinophils
- Eliminating pharmaceutical rebates, is this déjà vu?
- Bayer pays an initial $2bn for gene therapy firm AskBio
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- Exploring the potential of eosinophils
- GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
- Eliminating pharmaceutical rebates, is this déjà vu?
- By Andrew Parece and Matthew Majewski...
- Patients are ready to embrace decentralised clinical trials, are you?
- Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Quick links
Infographics
